Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / BIIB - Week In Review: InnoCare Strikes $937 Million Deal With Biogen For BTK Inhibitor

BIIB - Week In Review: InnoCare Strikes $937 Million Deal With Biogen For BTK Inhibitor

Biogen Inc.
  • Beijing InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen in a $937.5 million deal.
  • Suzhou's Kintor Pharma will start a US Phase II trial of its treatment for male pattern baldness.
  • Ascletis Pharma of Hangzhou started a China bridging trial of its FXR agonist following a successful US Phase I trial of ASC42 in healthy patients.

For further details see:

Week In Review: InnoCare Strikes $937 Million Deal With Biogen For BTK Inhibitor
Stock Information
Company Name: Biogen Inc.
Stock Symbol: BIIB
Market: NASDAQ
Website: biogen.com
Menu
BIIB BIIB Quote BIIB Short BIIB News BIIB Articles BIIB Message Board
Get BIIB Alerts

News, Short Squeeze, Breakout and More Instantly...